Addex Therapeutics vs Incannex Healthcare
ADXN and IXHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADXN and IXHL compare
Incannex Healthcare scores higher on the StockData Score (7 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | IXHL |
|---|---|---|
| Size and price | ||
| Market cap | – | $21.8M |
| Share price | $3.50 | $1.74 |
| Change, 1 year | −58.7% | −83.5% |
| Change, 5 years | −97.5% | – |
| Beta (5Y) | 1.95 | 2.40 |
| Employees | 3 | 12 |
| StockData Score | ||
| Total score | 0 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.3× |
| FCF yield | – | −14.6% |
| Growth | ||
| Revenue growth (TTM) | −92.6% | – |
| Revenue growth, 5Y average | −61.6% | – |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Operating margin | −9391% | – |
| FCF margin | −7244% | – |
| Return on equity | – | −20.7% |
| Return on invested capital | – | −1945% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −181.0× | – |
| Current ratio | 0.76 | 67.79 (better) |
| Altman Z-score | – | −0.22 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −42.2% |
| Shareholder yield | – | −42.2% |
| Ownership | ||
| Held by institutions | 0.00% | 3.6% |
| Held by insiders | 15.5% | – |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.